Imagen de Portada

New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice

Guardado en:
Publicado en:Helicobacter (Online) vol. 22, no. 3 (Jun 2017), p. n/a
Autor principal: Tursi, Antonio
Otros Autores: Di Mario, Francesco, Franceschi, Marilisa, De Bastiani, Rudi, Elisei, Walter, Baldassarre, Gianluca, Ferronato, Antonio, Grillo, Simone, Landi, Stefano, Zamparella, Maria, De Polo, Manuela, Boscariolo, Laura, Picchio, Marcello
Publicado:
Wiley Subscription Services, Inc.
Materias:
Antibiotic resistance
Bismuth
Omeprazole
Smoking
Clinical medicine
Confidence intervals
Patients
Diarrhea
Safety
Metronidazole
Urea
Antibiotics
Therapy
Potassium
Eradication
Helicobacter pylori
Social
Acceso en línea:Citation/Abstract
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:Background Rising antibiotic resistance requires the evaluation of new and effective therapies. Aims To test the efficacy and safety of the new bismuth-containing quadruple therapy in patients infected with Helicobacter pylori. Material and Methods Consecutive H. pylori-positive dyspeptic patients were enrolled, either naïve or with previous failure treatment. Patients were treated with Pylera (three-in-one capsules containing bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline 125 mg) three capsules q.i.d. plus omeprazole 20 mg or esomeprazole 40 mg b.i.d. for 10 days. Eradication was confirmed using an urea breath test (at least 30 days after the end of treatment). Efficacy was assessed by UBT and safety by means of treatment-emergent adverse events. Results One hundred and thirty-one patients were included in the study: 42% of patients were naïve, and 58%, with previous failure treatment. H. pylori eradication was achieved in 124 patients (94.7%, 95% confidence intervals (CIs) 89.3-97.8) in ITT population. In the PP population, the percentage was 97.6% (95%, CIs 93.3-99.2). No difference in eradication rate was found either between naïve and previously treated patients (92.7% vs 96.0%, P=.383), or smoking and nonsmoking ones, or in patients taking omeprazole or esomeprazole. Treatment-emergent adverse events occurred in 35 patients (26.7%, 95% CIs 19.9-34.9). They were mild in all cases except in four, who discontinued the study due to diarrhea (three patients) and diffuse urticarial rush (one patient). Conclusions Pylera achieved a remarkable eradication rate in clinical practice, irrespective if it was used as first treatment or as a rescue therapy. Treatment-emergent adverse events were uncommon generally mild.
ISSN:1523-5378
DOI:10.1111/hel.12371
Fuente:Health & Medical Collection